Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes

od KOKUFU, IKUO, KOHNO, NORIO, YAMAMOTO, MASAYUKI, TAKAO, SHINTARO
Izdano 2010

Projecting the impacts of rising seawater temperatures on the distribution of seaweeds around Japan under multiple climate change scenarios

od Takao, Shintaro, Kumagai, Naoki H, Yamano, Hiroya, Fujii, Masahiko, Yamanaka, Yasuhiro
izdano v Ecol Evol (2015)

Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer

od Yamashita, Yuji, Nishiumi, Shin, Kono, Seishi, Takao, Shintaro, Azuma, Takeshi, Yoshida, Masaru
izdano v BMC Cancer (2017)

Ocean currents and herbivory drive macroalgae-to-coral community shift under climate warming

od Kumagai, Naoki H., García Molinos, Jorge, Yamano, Hiroya, Takao, Shintaro, Fujii, Masahiko, Yamanaka, Yasuhiro
izdano v Proc Natl Acad Sci U S A (2018)

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

od Yamashita, Yuji, Tanaka, Yuko, Kono, Seishi, Nishimura, Meiko, Mukohara, Toru, Morinaga, Yukiko, Hara, Shigeo, Takao, Shintaro
izdano v Breast Care (Basel) (2017)

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Stud...

od Kikawa, Yuichiro, Kotake, Takeshi, Kajiwara, Yukiko, Hashimoto, Kazuki, Yamashiro, Hiroyasu, Ohtani, Shoichiro, Takao, Shintaro, Toi, Masakazu
izdano v Breast Cancer (Auckl) (2019)

Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer

od WATANABE, JUNICHIRO, ITO, YOSHINORI, SAEKI, TOSHIAKI, MASUDA, NORIKAZU, TAKANO, TOSHIMI, TAKAO, SHINTARO, NAKAGAMI, KAZUHIKO, TSUGAWA, KOICHIRO, NAKAGAWA, SHINTARO, KANATANI, KAZUMITSU, NAKAYAMA, TAKAHIRO
izdano v In Vivo (2017)

Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study

od Odan, Nina, Kikawa, Yuichiro, Matsumoto, Hajime, Minohata, Junya, Suwa, Hirofumi, Hashimoto, Takashi, Okuno, Toshitaka, Miyashita, Masaru, Saito, Masaru, Yamagami, Kazuhiko, Takao, Shintaro
izdano v Breast Cancer (Auckl) (2020)

Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer

od Ishiguro, Hiroshi, Ohno, Shinji, Yamamoto, Yutaka, Takao, Shintaro, Sato, Nobuaki, Fujisawa, Tomomi, Kadoya, Takayuki, Kuroi, Katsumasa, Bando, Hiroko, Teramura, Yasufumi, Iwata, Hiroji, Tanaka, Shiro, Toi, Masakazu
izdano v Breast Cancer (2019)

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid

od Yanae, Masashi, Fujimoto, Shinichiro, Tane, Kaori, Tanioka, Maki, Fujiwara, Kimiko, Tsubaki, Masanobu, Yamazoe, Yuzuru, Morishima, Yoshiyuki, Chiba, Yasutaka, Takao, Shintaro, Komoike, Yoshifumi, Tsurutani, Junji, Nakagawa, Kazuhiko, Nishida, Shozo
izdano v J Bone Oncol (2017)

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil...

od Ohno, Shinji, Saji, Shigehira, Masuda, Norikazu, Tsuda, Hitoshi, Akiyama, Futoshi, Kurosumi, Masafumi, Shimomura, Akihiko, Sato, Nobuaki, Takao, Shintaro, Ohsumi, Shozo, Tokuda, Yutaka, Inaji, Hideo, Watanabe, Toru, Ohashi, Yasuo
izdano v Breast Cancer Res Treat (2020)

Upregulation of S100A10 in metastasized breast cancer stem cells

od Yanagi, Hisano, Watanabe, Takashi, Nishimura, Tatsunori, Hayashi, Takanori, Kono, Seishi, Tsuchida, Hitomi, Hirata, Munetsugu, Kijima, Yuko, Takao, Shintaro, Okada, Seiji, Suzuki, Motoshi, Imaizumi, Kazuyoshi, Kawada, Kenji, Minami, Hironobu, Gotoh, Noriko, Shimono, Yohei
izdano v Cancer Sci (2020)

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

od Aogi, Kenjiro, Watanabe, Kenichi, Kitada, Masahiro, Sangai, Takafumi, Ohtani, Shoichiro, Aruga, Tomoyuki, Kawaguchi, Hidetoshi, Fujisawa, Tomomi, Maeda, Shigeto, Morimoto, Takashi, Sato, Nobuaki, Takao, Shintaro, Morita, Satoshi, Masuda, Norikazu, Toi, Masakazu, Ohno, Shinji
izdano v Int J Clin Oncol (2021)

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

od Hasegawa, Yoshie, Tanino, Hirokazu, Horiguchi, Jun, Miura, Daishu, Ishikawa, Takashi, Hayashi, Mitsuhiro, Takao, Shintaro, Kim, Seung Jin, Yamagami, Kazuhiko, Miyashita, Masaru, Konishi, Muneharu, Shigeoka, Yasushi, Suzuki, Masato, Taguchi, Tetsuya, Kubota, Tomoyuki, Akazawa, Kouhei, Kohno, Norio
izdano v PLoS One (2015)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

od Watanabe, Junichiro, Ito, Yoshinori, Ohsumi, Shozo, Mizutani, Mitsuhiro, Tashiro, Hideya, Sakurai, Kenichi, Takahashi, Masato, Saito, Tsuyoshi, Tsurutani, Junji, Mukai, Hirofumi, Yoshinami, Tetsuhiro, Takao, Shintaro, Yamamoto, Yasuhisa, Matsuoka, Toshiyuki, Iwase, Hirotaka, Iwata, Hiroji, Nakamura, Seigo, Saeki, Toshiaki
izdano v Invest New Drugs (2017)

Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer

od Tamura, Kenji, Inoue, Kenichi, Masuda, Norikazu, Takao, Shintaro, Kashiwaba, Masahiro, Tokuda, Yutaka, Iwata, Hiroji, Yamamoto, Naohito, Aogi, Kenjiro, Saeki, Toshiaki, Nakayama, Takahiro, Sato, Nobuaki, Toyama, Tatsuya, Ishida, Takanori, Arioka, Hitoshi, Saito, Mitsue, Ohno, Shinji, Yamauchi, Hideko, Yamada, Kimito, Watanabe, Junichiro, Ishiguro, Hiroshi, Fujiwara, Yasuhiro
izdano v Cancer Sci (2017)